Q1 2025

Filed Aug 11, 2025 · 10-Q · 42 days after period end · 0001140361-25-030001

Q1 2025 · 10-Q

Revenue

$2.17M

−72.8% vs Q1 2024

Net Income

-$223.36M

N/M vs Q1 2024

EPS Diluted

-$0.33

N/M vs Q1 2024

Operating Income-$284,922,000N/M

Operating Cash Flow

Same quarter

Metric	Q1 2025	Q1 2024	Q1 2023	Q1 2022
Revenue	$2.17M	$7.99M	$21.62M	$4.32M
Net Income	-$223.36M	$95.30M	-$291.82M	-$331.81M
EPS Diluted	-$0.33	$0.12	-$0.38	-$0.48

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR